The EMA is working with social media content creators to try to encourage "safe and responsible" use of weight-loss drugs.

A boardroom shake-up at Novo Nordisk has handed unprecedented power to its top shareholder, the Novo Nordisk Foundation, ...

Another week, another twist in the turnaround efforts at Novo Nordisk, the maker of the blockbuster Ozempic and Wegovy weight ...

Dive deeper with STAT+. Gain unlimited access to expert analysis, newsletters, events, and news alerts.

A new analysis finds that the heart-protecting benefits of semaglutide are largely independent of its weight loss effects.

Shares of Eli Lilly and Novo Nordisk fell Friday, Oct. 17 after Pres. Donald Trump said the price of the weight-loss drug Ozempic could soon drop to $150 a month.

"Charles Barkley is going on the offense after seeing his weight rebound. The NBA Hall of Famer has signed on as GLP-1 ...

Novo Nordisk (NVO) recruits top healthcare analyst Michael Novod, a long time bull of the company, as head of its investor ...

Prescription-drug costs were the top-cited factor for rising premiums, according to large businesses surveyed by the think tank. Two-thirds of large businesses said GLP-1s for weight loss had a ...

Once-weekly semaglutide 2.4 mg conferred a greater reduction in major adverse cardiovascular events than placebo, regardless ...

Karen Finerman, CEO & Co-founder, Metropolitan Capital Advisors, said in a recent program on CNBC that she likes NVO amid the ...

Novo Nordisk Chairman Helge Lund is stepping down after clashing with the company’s main shareholder, the Novo Nordisk ...